77
Participants
Start Date
June 12, 2019
Primary Completion Date
June 30, 2025
Study Completion Date
June 30, 2026
SX-682
SX-682 is an oral small molecule selective inhibitor of C-X-C Motif Chemokine Receptor 1 (CXCR1) and C-X-C Motif Chemokine Receptor 2 (CXCR2)
Pembrolizumab
Pembrolizumab is a humanized antibody that targets the programmed cell death 1 receptor (PD-1).
RECRUITING
Wilmot Cancer Institute - University of Rochester, Rochester
RECRUITING
University of Miami, Miami
RECRUITING
Mayo Clinic, Rochester
RECRUITING
MD Anderson, Houston
ACTIVE_NOT_RECRUITING
Massachusetts General Hospital Cancer Center, Boston
ACTIVE_NOT_RECRUITING
Dana-Farber Cancer Institute, Boston
Collaborators (1)
Massachusetts General Hospital
OTHER
National Cancer Institute (NCI)
NIH
Dana-Farber Cancer Institute
OTHER
Mayo Clinic
OTHER
University of Rochester
OTHER
M.D. Anderson Cancer Center
OTHER
University of Miami
OTHER
Syntrix Biosystems, Inc.
INDUSTRY